Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Table 1 Demographic and baseline characteristics of the patients

Patient Characteristics	ALL patients (Number (percent))
Total no. of patients	30 (100)
Median age, years (range)	55 (26–74)
Sex
Female	8 (27)
Male	22 (73)
Metastatic stage (n)
M0	1 (3)
M1a	6 (20)
M1b	6 (20)
M1c	17 (57)
Lactate dehydrogenase
≤ ULN^a	20 (67)
> ULN	10 (33)
ECOG
0	19 (63)
1	11 (37)
Primary site
Cutaneous	24 (80)
Mucosal	2 (7)
Ocular	3 (10)
Unknown primary	1 (3)
BRAF status
BRAF mutated (V600E)	9 (30)
BRAF wild type	21 (70)
Prior therapies**
Prior adjuvant therapy	5 (17)
Prior therapy with a BRAF inhibitor	6 (20)
Brain metastases
Patients without brain metastases	26 (87)
Patients with brain metastases	4 (13)

^aULN denotes upper limit of the normal, ** One patient (3%) received 2 weeks a of Temozolomide